Novo Nordisk has significantly slashed prices for Ozempic and Wegovy in India, reducing them by 36% and 48% respectively, to enhance patien...

The expiry of a key patent for semaglutide in India opens doors for affordable weight-loss and diabetes drugs. Indian pharmaceutical compan...

Eli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite ...

Dr Reddy's Laboratories is set to launch a generic version of semaglutide in India on March 21. The company plans to offer both oral and in...

UBS has initiated coverage on Shaily Engineering Plastics with a Buy rating and a target price of Rs 4,000, citing strong growth prospects ...

Novo Nordisk India head Vikrant Shrotriya revealed a strategic 37% price cut for obesity drug Wegovy, aiming for wider accessibility. The c...

In June, Novo Nordisk launched Wegovy (semaglutide) injections in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg). However, the compan...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand n...

Eli Lilly plans to launch an oral weight loss drug, orforglipron, after Mounjaro's India success. Regulatory submissions are expected soon,...

The World Health Organization has included Semaglutide and Tirzepatide, popular weight-loss drugs, in its Model List of Essential Medicines...

The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-...

As weight-loss drug sales surge with semaglutide's patent expiration, Gujarat's Shaily Engineering Plastics, an injector pen manufacturer, ...

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gain...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record for prescriptio...

A new study into GLP-1RA drugs provides previously unknown insights into the impact this class of drugs may have on eating habits. The stud...

India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenge...

Novo Nordisk, the Danish drug maker on Thursday announced the launch of oral semaglutide in India for treatment of type 2 diabetes.